AI assistant
Dechra Pharmaceuticals PLC Remuneration Information 2020
4797_def-14a_2020-10-20_63a46c2b-f0ec-47c5-82bb-e02f8c4d76d8.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 6654C
Dechra Pharmaceuticals PLC
20 October 2020
20 October 2020
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
LEI: 213800J4UVB5OWG8VX82
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Grant of SAYE options:
Dechra Pharmaceuticals PLC announces that on 19 October 2020 the following PDMRs were granted options over ordinary shares of 1p each in the Company pursuant to the Dechra Global Save As You Earn Plan 2018 (the Options).
The Options have been granted with an exercise price of £28.68.
| Name | Capacity | Options Granted |
| Ian Page | Director | 627 |
| Paul Sandland | Director | 627 |
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Ian Page | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Grant of 627 options under the Company's Save As You Earn Scheme | |
| c) | Price(s) and volumes(s) | Price(s) £28.68 |
Volume(s) 627 |
| d) | Aggregated information - Aggregate volume - Price |
627 £17,982.36 |
|
| e) | Date of the transaction | 2020.10.19 | |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Paul Sandland | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Grant of 627 options under the Company's Save As You Earn Scheme | |
| c) | Price(s) and volumes(s) | Price(s) £28.68 |
Volume(s) 627 |
| d) | Aggregated information - Aggregate volume - Price |
627 £17,982.36 |
|
| e) | Date of the transaction | 2020.10.19 | |
| f) | Place of the transaction | Outside a trading venue |
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHKKKBPKBDDCKB